Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

daclizumab

- PMLiVE

Double trial disappointment for Roche

Discontinues Alzheimer’s programme and finds Kadcyla no better than Herceptin in certain breast cancer

- PMLiVE

Alzheimer’s charity launches £20m trials fund

Aims to fast-track research into dementia treatments

- PMLiVE

Biogen Idec launches online multiple sclerosis programme

MS Blueprint aims to help people with MS develop a personalised support plan

MS market set to grow 4% annually

Predictedto reach $20bn by 2023 partly due to Plegridy and ocrelizumab launches

Novartis building

Novartis launches Alzheimer’s prevention study

Will test two treatments in people with genetic risk of dementia

- PMLiVE

Another Alzheimer’s failure as Targacept trial disappoints

Targacept drops development of drug after disappointing study results

- PMLiVE

AFFiRiS claims a first in Alzheimer’s disease therapy

Says AD04 is first drug to demonstrate disease modification

Bristol-Myers Squibb (BMS) building

BMS buys Alzheimer’s player iPierian in $725m deal

Takes control of several promising candidates for neurodegenerative diseases

Biogen Idec building

Eisai and Biogen partner on Alzheimer’s

Will co-develop two drug candidates

- PMLiVE

G8 sets 2025 target for effective dementia treatment

World leaders pledge more research funding

- PMLiVE

Merck takes Alzheimer’s hope into phase III

MK-8931 moves to late-stage study after positive early data

- PMLiVE

IMI launches dementia trials alliance

EU group wants to revamp approach to Alzheimer’s research

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links